Search Results
Jan 15, 2026, 00:29 ET Merz Aesthetics® 委任韓國女星宋慧喬為 BELOTERO® 亞太區品牌大使 引領仿生透明質酸療程 宣揚細節成就自然美
Vandeputte J. J Clin Aesthet Dermatol. 2018 Dec;11(12):30-39.[17] Corduff N, et al. A New Way of Classifying Hyaluronic Acid Fillers: The AART Classification. Clin Cosmet Investig
More news about: Merz Aesthetics®
Jan 13, 2026, 09:22 ET This Year Adopt Brain-boosting Habits
of dietary choline intake with risk of incident dementia and with cognitive performance: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr. 2019 Dec 1;110(6):1416-1423. doi: 10.1093/ajcn/nqz148. PMID:
More news about: The Peanut Institute
Jan 13, 2026, 08:00 ET Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
10.1176/ajp.2006.163.Arnaud AM, Brister TS, Duckworth K, et al. Impact of major depressive disorder on comorbidities: a systematic literature review. J Clin Psychiatry. 2022;83(6):21r14328.Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr
More news about: Johnson & Johnson
Jan 13, 2026, 07:37 ET Tulavi Therapeutics Receives Innovative Technology Contract from Vizient for the allay™ Hydrogel Cap
Hobusch GM. How Common Are Chronic Residual Limb Pain, Phantom Pain, and Back Pain More Than 20 Years After Lower Limb Amputation for Malignant Tumors? Clin Orthop Relat Res. 2021 Sep 1;479(9):2036-2044. doi: 10.1097/CORR.0000000000001725. PMID: 33739309; PMCID: PMC8373555.Dellon, A. L. (2001).
More news about: Tulavi Therapeutics, Inc.
Jan 12, 2026, 10:00 ET Freenome Announces Expanded Artificial Intelligence and Deep Learning Initiatives Accelerated by NVIDIA, to Advance Personalized Multi-Cancer Detection
intelligence and machine learning to tune into cancer's subtlest clues, even at the earliest stages of the disease.References1. Clin Cancer Res (2025) 31 (13_Supplement): A045. doi/10.1158/aimachine-A045
More news about: Freenome Holdings, Inc.
Jan 12, 2026, 09:20 ET Lung Cancer Research Foundation and Oncology Advocates United for Climate and Health - International Announce Request for Proposals Now Open for Submission
to air pollution has increased by nearly 30% since 2007, as smoking has decreased and air pollution has increased (Turner MC et al, CA Cancer J Clin, 2020). The International Agency for Research on Cancer (IARC) has classified outdoor air pollution and particulate matter (PM) with a diameter of
More news about: Lung Cancer Research Foundation
Jan 12, 2026, 08:05 ET Rigel Provides Business Update and 2026 Outlook
https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.htmlKato, S. et al. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017;23(8):1988-1997 doi: 10.1158/1078-0432.CCR-16-1679The American Cancer Society. Key Statistics for Acute Myeloid Leukemia (AML).
More news about: Rigel Pharmaceuticals, Inc.
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Endometrial Cancer Risk Factors, 2025 6. Leslie KK, et al. Gynecol Oncol. 2021;161(1):113-121. 7. Vergote I, et al. J Clin Oncol. 2023;41(35):5400-5410. 8. Mirza MR, et al. Presentation at: ESMO Congress; October 20-24, 2023 9. Mirza
More news about: Karyopharm Therapeutics Inc.
Jan 10, 2026, 10:00 ET RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res. 2015;21(24):5469-5479. doi:10.1158/1078-0432.CCR-15-052611 Feldt SL, Bestvina CM. The Role of MET in Resistance
More news about: Johnson & Johnson
Jan 09, 2026, 09:43 ET Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
SANDOSTATIN® LAR Ferone, D., et al. Octreotide subcutaneous depot for acromegaly: A randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1. J Clin Endocrinol Metab. Published 8 October, 2024.
More news about: Camurus AB
Jan 09, 2026, 09:36 ET Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
SANDOSTATIN® LAR Ferone, D., et al. Octreotide subcutaneous depot for acromegaly: A randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1. J Clin Endocrinol Metab. Published 8 October, 2024.
More news about: Camurus AB
Jan 05, 2026, 08:00 ET Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson's Disease
moderate-severe idiopathic Parkinson's disease. Initial safety, tolerability and brain imaging data from all 12 patients are expected in 2026.CIRM's CLIN2 program supports regenerative medicine therapies through key stages of clinical development, providing funding to help advance promising treatments
More news about: Kenai Therapeutics/BIOCOM
Jan 05, 2026, 06:50 ET Protalix BioTherapeutics Letter to Stockholders
[email protected] Punzi L, Scagnellato L, Galozzi P, et al. Gout: one year in review 2025. Clin Exp Rheumatol. 2025;43(5):799–808.2 Jacobsen J, Shattler K. Gout Statistics & Facts 2025. HealthCanal. Published November
More news about: Protalix BioTherapeutics, Inc.
Dec 25, 2025, 03:45 ET China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
iii. Sargent DJ, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219-3226. doi:10.1200/JCO.2009.27.1825
More news about: Innovent Biologics
Dec 22, 2025, 09:00 ET Merz Aesthetics® Expert Summit Latam 2025 discute tendencias de la medicina estética y lanza nuevos protocolos de tratamiento
países. ASSETR-2902 11/2025.Referencias1. de Sanctis Pecora C. The Anatomical Layering Assessment: The Construction of Beauty. Clin Cosmet Investig Dermatol. 2024 Mar 13;17:605-20.2. de Sanctis Pecora C. Corduff N, Carroll J, Muniz M, Sattler S. Multimodal Treatment Combinations
More news about: Merz Aesthetics Latam
Dec 22, 2025, 06:00 ET Merz Aesthetics® Expert Summit Latam 2025 discute tendências da medicina estética e lança novos protocolos de tratamento
países. ASSETR-2902 11/2025.Referências1. de Sanctis Pecora C. The Anatomical Layering Assessment: The Construction of Beauty. Clin Cosmet Investig Dermatol. 2024 Mar 13;17:605-20.2. de Sanctis Pecora C. Corduff N, Carroll J, Muniz M, Sattler S. Multimodal Treatment Combinations
More news about: Merz Aesthetics Latam
Dec 19, 2025, 09:00 ET Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel in a Head-to-Head Phase 3 Trial
2025 3 Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–11924 Olmos, D. et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer
More news about: TOLMAR
Dec 18, 2025, 09:52 ET Brasil é o primeiro país a aprovar imunobiológico para pacientes pediátricos com Urticária Crônica Espontânea
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024 Jul;154(1):184-194.7 IQVIA/Sanofi Integrated DUPIXENT platform, data through August, 2024.
More news about: Sanofi
Dec 17, 2025, 18:49 ET U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024 Oct 20;42(30):3593-3605.ClinicalTrials.gov. A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab
More news about: Johnson & Johnson
Dec 17, 2025, 14:15 ET O segredo da musa! Sabrina Sato revela a sua rotina de cuidados com a pele para a temporada de verão e Carnaval
presented at AMWC 2019. 16. Weiss RA, et al. Dermatol Surg. 2016 Jun;42(6):699-709 17. Di Gregorio C, et al. Clin Cosmet Investig Dermatol. 2022 Apr 14;15:681-690. 18. Belmontesi M, et al. J Drugs Dermatol. 2018 Jan 1;17(1):83-88. 19.
More news about: Galderma
Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
.iv Funt SA, Rosenberg JE. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol. 2017 Apr;14(4):221-234. doi: 10.1038/nrclinonc.2016.188. Epub 2016 Nov 22. PMID: 27874062; PMCID: PMC6054138.v Squires
More news about: Astellas Pharma Inc.
Dec 16, 2025, 07:30 ET REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
FoundationAlhanshali L, Buontempo MG, Lo Sicco KI, Shapiro J. Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs. Clin Cosmet Investig Dermatol. 2023;16:803-820 https://doi.org/10.2147/CCID.S376096
More news about: Nektar Therapeutics
Dec 15, 2025, 23:55 ET Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
[2] JAMA Oncol. 2025;11;(8):883-889.[3] Lin, N. U., et al. Soc. Clin. Oncol. Educ. Book 37, 45-56 (2017).
More news about: Biostar Pharma, Inc.
Dec 12, 2025, 20:25 ET U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
patterns and survival outcomes among androgen receptor pathway inhibitor-experienced patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2024;22(6):1-14. doi:10.1016/j.clgc.2024.102188
More news about: Johnson & Johnson
Dec 12, 2025, 13:23 ET Efeitos imediatos: descobrimos os tratamentos que vão recuperar o glow da sua pele a tempo de aproveitar as festas de final de ano
Surg. 2014;20(2):97-1036. Weiss RA, et al. Dermatol Surg. 2016 Jun;42(6):699-7097. Di Gregorio C, et al. Clin Cosmet Investig Dermatol. 2022 Apr 14;15:681-690.8. Talarico S, et al. Dermatol Surg. 2015 Dec;41(12):1361-9.9. Kerscher
More news about: Galderma